Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma

Tasuku Hara; Kohei Oka; Naoto Iwai; Yutaka Inada; Toshifumi Tsuji; Takashi Okuda; Akihiro Nagata; Toshiyuki Komaki; Keizo Kagawa

doi:10.2169/internalmedicine.5678-20

CASE REPORTS

Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma

Tasuku Hara, Kohei Oka, Naoto Iwai, Yutaka Inada, Toshifumi Tsuji, Takashi Okuda, Akihiro Nagata, Toshiyuki Komaki, Keizo Kagawa

Author information

Tasuku Hara
Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan
Kohei Oka
Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan
Naoto Iwai
Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan
Yutaka Inada
Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan
Toshifumi Tsuji
Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan
Takashi Okuda
Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan
Akihiro Nagata
Department of Pathology, Fukuchiyama City Hospital, Japan
Toshiyuki Komaki
Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan
Keizo Kagawa
Department of Gastroenterology and Hepatology, Fukuchiyama City Hospital, Japan

Keywords: hepatitis B virus reactivation, de novo hepatitis, rituximab, peripheral blood stem cell transplantation

JOURNAL OPEN ACCESS

2021 Volume 60 Issue 3 Pages 417-421

DOI https://doi.org/10.2169/internalmedicine.5678-20

Browse “Advance online publication” version

Details

Abstract

A 54-year-old woman underwent chemotherapy including rituximab and autologous peripheral blood stem cell transplantation (auto-PBSCT) for diffuse large B-cell lymphoma. Before the treatment, she exhibited a resolved hepatitis B virus (HBV) infection. She was diagnosed with HBV reactivation based on positive serum HBV-DNA test results, 55 months after her last treatment. Subsequently, he was treated with tenofovir alafenamide fumarate (TAF) therapy and her liver function improved. Patients undergoing chemotherapy including rituximab and auto-PBSCT are at a high risk of HBV reactivation. In such cases, careful and long-term observations may be required to detect HBV reactivation.

Corresponding author

Register with J-STAGE for free!